CN1695606A - Technique for producing re-dissolvable lysine hydrochloride in use for injection - Google Patents
Technique for producing re-dissolvable lysine hydrochloride in use for injection Download PDFInfo
- Publication number
- CN1695606A CN1695606A CN 200510010023 CN200510010023A CN1695606A CN 1695606 A CN1695606 A CN 1695606A CN 200510010023 CN200510010023 CN 200510010023 CN 200510010023 A CN200510010023 A CN 200510010023A CN 1695606 A CN1695606 A CN 1695606A
- Authority
- CN
- China
- Prior art keywords
- injection
- dissolvable
- lysine hydrochloride
- producing
- technique
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
A process for preparing the quickly dissolving powder injection of lysine hydrochloride is disclosed.
Description
Technical field:
Lysine is one of essential amino acid, and some metabolic process that it not only participates in body also influences other amino acid whose absorptions, metabolism.Existing result of study shows: lysine can suppress duplicating of simple scar exanthema virus, angina pectoris, myocardial infarction there is preventive effect, reduce the sickness rate of essential hypertension rat brain apoplexy, improve loss of memory patient's memory function, itself also have barbital sample anticonvulsant action.
One of can not synthetic 8 kinds of essential amino acids as human body, lysine produces glutaryl coenzyme A in the metabolism in vivo, the further metabolism of the latter generates S-acetyl-coenzyme-A and a small amount of ketoglutaric acid.Coenzyme A can be used as the auxiliary treatment of brain illness, and simultaneously, S-acetyl-coenzyme-A produces a large amount of adenosine triphosphate after entering tricarboxylic acid cycle; knot human body anabolism provides enough energy; the king-sized brain cell that consumes energy is played protective effect, improved the vigor of cerebral tissue, helped the damaged tissue reparation.Lysine itself more easily sees through blood brain barrier, and this also is one of its reason evident in efficacy.As seen in numerous brain function rehabilitation medicines, Medicinal L-Lysine is one of a kind of medicine of brain rehabilitation efficiently, and untoward reaction is minimum, is worth clinical application.
Formulation and technology:
| Supplementary material | Specification |
| Prescription 1 | |
| Lysine hydrochloride | ??3000g |
| Ethanol | ??50ml |
| Mannitol | ??50g |
| Sodium chloride | ??50g |
| Water for injection adds to | ??10L |
| Make | 1000 bottles |
Preparation technology
(1) butyl rubber plug, control cillin bottle (specification 25ml) etc. are sterilized all by injection routine requirement cleaning treatment.
(2) the indoor lysine hydrochloride (prescription 2 adds the mannitol and the sodium chloride of recipe quantity) that accurately takes by weighing recipe quantity in the sterile working places suitable sterile chamber, adds injection water (50 ℃) to 9L, stirs and makes dissolving.(prescription 3 adds that the ethanol of recipe quantity stirs evenly)
(3) control pH (transfers pH with the 0.5mol/L hydrochloric acid solution) in 5.0～6.0 scopes in case of necessity, adds 0.05% (g/ml) needle-use activated carbon, and insulated and stirred is after 20 minutes, filtering decarbonization.Add water for injection (50 ℃) to 10L, use the microporous filter membrane aseptic filtration successively of 0.45 μ m microporous filter membrane and 0.22 μ m respectively.
(4) filtrate censorship qualified after, according to the loading amount of each specification, aseptic subpackaged in vial.
(5) lyophilization
(6) packing, full inspection, warehouse-in.
Summary of the invention: a kind of production technology of re-dissolvable lysine hydrochloride in use for injection.Unique Recipe makes product accelerate greatly in redissolution speed.
The invention has the advantages that: improved the redissolution speed of lysine hydrochloride greatly, clinical practice is more convenient, and has increased the stability of product.
Claims (2)
1. the production technology of a re-dissolvable lysine hydrochloride in use for injection.It is characterized by adjuvants such as using ethanol, sodium chloride, mannitol jointly as support, finished product has the fast characteristics of dissolving.
2. the technology according to the described a kind of re-dissolvable lysine hydrochloride in use for injection of claim (1) is characterized in that, it can be each unit package 0.1-10g that this technology is used for the injectable powder specification.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010023 CN1695606A (en) | 2005-05-25 | 2005-05-25 | Technique for producing re-dissolvable lysine hydrochloride in use for injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510010023 CN1695606A (en) | 2005-05-25 | 2005-05-25 | Technique for producing re-dissolvable lysine hydrochloride in use for injection |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1695606A true CN1695606A (en) | 2005-11-16 |
Family
ID=35348595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510010023 Pending CN1695606A (en) | 2005-05-25 | 2005-05-25 | Technique for producing re-dissolvable lysine hydrochloride in use for injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1695606A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988304A (en) * | 2012-07-12 | 2013-03-27 | 姚云 | Medicinal composition containing lysine hydrochloride compound |
-
2005
- 2005-05-25 CN CN 200510010023 patent/CN1695606A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102988304A (en) * | 2012-07-12 | 2013-03-27 | 姚云 | Medicinal composition containing lysine hydrochloride compound |
| CN102988304B (en) * | 2012-07-12 | 2014-04-16 | 姚云 | Medicinal composition containing lysine hydrochloride compound |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4192114B2 (en) | Cyclic adhesion inhibitor | |
| KR101115557B1 (en) | Biologically non-degradable peptide, angiotensin converting enzyme inhibitor, drug and functional food | |
| US3369969A (en) | Colibacilli containing medicament and a method of preparing same | |
| KR20010108389A (en) | Compositions for promoting growth | |
| JP6010196B2 (en) | Oxazolidinone-containing dimer compounds, compositions, and methods of making and using | |
| CN1572318A (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
| CN106659711A (en) | Durable preparation of an injectable of melatonin exhibiting long-term stability | |
| CN107519127A (en) | A kind of ambroxol hydrochloride injection and preparation method thereof | |
| CN102626409A (en) | Pharmaceutical composition containing 18 amino acids | |
| CN1695606A (en) | Technique for producing re-dissolvable lysine hydrochloride in use for injection | |
| CN104262481A (en) | Preparing method and applications of long-acting GLP-1 analogues modified with side chains | |
| US6270750B1 (en) | Proline-, glycine- and lysine-based pharmaceutical composition useful in dental treatment both in the injectable form and in the formulation for topical use | |
| CN101157726A (en) | Deuterohemin short-peptide compound and its application in preparation of anti-cataractogenesis drugs | |
| CN102283804A (en) | Meglumine adenosine cyclophosphate injection and preparation method thereof | |
| WO1999055325A1 (en) | Drugs for reducing vaginal acidity and treatment of vaginitis, and the use thereof | |
| CN1615906A (en) | 18 compound amino acid injection and its preparing method | |
| RU2011131772A (en) | ANGIOGENESIS AMPLIFIERS AS A RESULT OF STROKE AND THEIR APPLICATION | |
| CN104587452B (en) | A kind of solution for preparing thymalfasin preparation and the method that thymalfasin preparation is prepared using the solution | |
| CN101336903B (en) | Preparation method of (s)-ornidazole disodium phosphate intravenous preparation for injection | |
| CN1839837A (en) | Nicorandil freeze-drying powder preparation method | |
| EP2454229B1 (en) | Amino acid derivatives for the treatment of neuropathic pain | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN101780099B (en) | Meglumine adenosine cyclophosphate composite medicament | |
| CN101066266A (en) | Organic salt of pyritinol and its prepn process | |
| CN101768156A (en) | Pidotimod arginine salt and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |